In the October 22, 2024 issue of JACC, a podcast explores the promising benefits of semaglutide, a glucagon-like peptide receptor agonist, in treating obesity-related heart failure. The episode discusses key findings from original research, highlighting how semaglutide improves cardiac structure and function, attenuates adverse remodeling, and showcases the dual mechanisms—both weight-related and independent—behind these effects.
JACC This Week